Reaction
Immune-Mediated Adrenal Insufficiency reporting signals
As of the last recalculation, Immune-Mediated Adrenal Insufficiency appears in 745 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 292.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 445 | 292.0 | 293.2 |
| Ipilimumab | 160 | 131.6 | 132.1 |
| Nivolumab | 244 | 104.4 | 104.6 |
| Lenvatinib | 91 | 88.1 | 88.4 |
| Paclitaxel (Aibumin-Bound) | 164 | 71.2 | 71.3 |
| Carboplatin | 207 | 62.7 | 62.8 |
| Paclitaxel | 170 | 61.8 | 61.9 |
| Durvalumab | 29 | 41.4 | 41.5 |
| Pemetrexed | 25 | 33.7 | 33.7 |
| Pemetrexed Disodium | 34 | 26.1 | 26.1 |
| Cyclophosphamide Injection, Solution | 84 | 14.8 | 14.8 |
| Cyclophosphamide | 84 | 14.8 | 14.8 |
| Cyclophosphamide For Injection | 84 | 14.8 | 14.8 |
| Atezolizumab | 18 | 13.2 | 13.3 |
| Cabozantinib | 18 | 10.7 | 10.7 |
| Encorafenib | 3 | 8.5 | 8.5 |